These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19763140)

  • 1. Conformational stability and activity of p73 require a second helix in the tetramerization domain.
    Coutandin D; Löhr F; Niesen FH; Ikeya T; Weber TA; Schäfer B; Zielonka EM; Bullock AN; Yang A; Güntert P; Knapp S; McKeon F; Ou HD; Dötsch V
    Cell Death Differ; 2009 Dec; 16(12):1582-9. PubMed ID: 19763140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural evolution of p53, p63, and p73: implication for heterotetramer formation.
    Joerger AC; Rajagopalan S; Natan E; Veprintsev DB; Robinson CV; Fersht AR
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17705-10. PubMed ID: 19815500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimerization of the core domain of the p53 family: a computational study.
    Madhumalar A; Jun LH; Lane DP; Verma CS
    Cell Cycle; 2009 Jan; 8(1):137-48. PubMed ID: 19106606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural investigations of the p53/p73 homologs from the tunicate species Ciona intestinalis reveal the sequence requirements for the formation of a tetramerization domain.
    Heering J; Jonker HR; Löhr F; Schwalbe H; Dötsch V
    Protein Sci; 2016 Feb; 25(2):410-22. PubMed ID: 26473758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.
    Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH
    J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p63 and p73: roles in development and tumor formation.
    Moll UM; Slade N
    Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
    Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
    Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
    Vilgelm A; El-Rifai W; Zaika A
    Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73.
    van Dieck J; Brandt T; Teufel DP; Veprintsev DB; Joerger AC; Fersht AR
    Oncogene; 2010 Apr; 29(14):2024-35. PubMed ID: 20140014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of functions within the p53/p63/p73 family.
    De Laurenzi V; Melino G
    Ann N Y Acad Sci; 2000; 926():90-100. PubMed ID: 11193045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From p63 to p53 across p73.
    Strano S; Rossi M; Fontemaggi G; Munarriz E; Soddu S; Sacchi A; Blandino G
    FEBS Lett; 2001 Feb; 490(3):163-70. PubMed ID: 11223031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
    Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
    Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tracing the protectors path from the germ line to the genome.
    Coutandin D; Ou HD; Löhr F; Dötsch V
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15318-25. PubMed ID: 20696896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p73 and p63: why do we still need them?
    Blandino G; Dobbelstein M
    Cell Cycle; 2004 Jul; 3(7):886-94. PubMed ID: 15254416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
    Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
    Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.
    Burge S; Teufel DP; Townsley FM; Freund SM; Bycroft M; Fersht AR
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3142-7. PubMed ID: 19218448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One billion years of p53/p63/p73 evolution.
    Belyi VA; Levine AJ
    Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17609-10. PubMed ID: 19826090
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in the transactivation domains of p53 family members: a computational study.
    Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
    BMC Genomics; 2010 Feb; 11 Suppl 1(Suppl 1):S5. PubMed ID: 20158876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 Family members p63 and p73 are SAM domain-containing proteins.
    Thanos CD; Bowie JU
    Protein Sci; 1999 Aug; 8(8):1708-10. PubMed ID: 10452616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code.
    Ciribilli Y; Monti P; Bisio A; Nguyen HT; Ethayathulla AS; Ramos A; Foggetti G; Menichini P; Menendez D; Resnick MA; Viadiu H; Fronza G; Inga A
    Nucleic Acids Res; 2013 Oct; 41(18):8637-53. PubMed ID: 23892287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.